Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 6/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 6/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 6/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 6/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 1.00 |
| ▸ | GSAP | A4D1B5 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.59 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453584 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29359226 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2679837 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29353214 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12462877 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL453583 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14418092 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413288 | 0.96 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413442 | 0.94 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4985301 | 0.93 | PSEN1 (0.88) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| WO-2019069327-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2019-04-11 | — | — | WO | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| US-20240279602-A1 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | KYOTO UNIVERSITY (JP) | 2024-08-22 | — | — | US | disclosed |
| WO-2024151804-A2 | METHODS AND MATERIALS FOR GENERATING STEM CELL-DERIVED ENDOCRINE CELL TYPES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240148789-A1 | Synergistic Inhibition of eIF5A and Notch Signaling | THE UNIVERSITY OF TOLEDO (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4357449-A1 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-116808219-A | Gamma secretase modulators for the treatment of immune system dysfunction | 安可初克公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | disclosed |
| US-20180258400-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2018-09-13 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-8173423-B2 | Diagnosis and treatment of T-cell acute lymphoblastic leukemia | VIB VZW (BE) | 2012-05-08 | — | — | US | disclosed |
| CN-102085372-A | Application of Notch pathway inhibitor in treatment of tumors caused by activation of mTOR | INST BASIC MED SCIENCES PLA | 2011-06-08 | — | — | CN | disclosed |
| US-20100130586-A1 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | VIB VZW (BE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PSEN1 3142/4885PSEN2 3508/4885APH1B 1089/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PSEN1 3142/4885PSEN2 3508/4885APH1B 1089/4885 |
| US-20240148789-A1 | Synergistic Inhibition of eIF5A and Notch Signaling | EIF2B5, EIF5B, EIF2B1 | PSEN1 2867/4885PSEN2 3369/4885APH1B 479/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PSEN1 2865/4885PSEN2 3896/4885APH1B 2827/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PSEN1 2754/4885PSEN2 3413/4885APH1B 1847/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PSEN1 3142/4885PSEN2 3508/4885APH1B 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.